# Atomoxetine

## Apo-Atomoxetine 18mg

| 藥物代碼 | OATMX |
| :--- | :--- |
| 適應症 | Attention deficit hyperactivity disorder |
| 副作用 | CommonCardiovascular: Increased heart rate \(Adult, 10.2% to 22.4%; pediatric, 12.2% to 23.4% \)Endocrine metabolic: Weight decreased \(Adult, 2%; pediatric, 3% \)Gastrointestinal: Abdominal pain \(Adult, 7%; pediatric, 18% \), Constipation \(Adult, 8%; pediatric, 1% to 2% \), Decrease in appetite \(Adult, 16%; pediatric, 16% \), Nausea \(Adult, 26%; pediatric, 10% \), Vomiting \(Adult, 4%; pediatric, 11% \), Xerostomia \(Adult, 20% \)Neurologic: Dizziness \(Adult, 8%; pediatric, 5% \), Headache \(Pediatric, 19% \), Insomnia \(Adult, 15%; pediatric, at least 2% \), Somnolence \(Adult, 8%; pediatric, 11% \)Renal: Delay when starting to pass urine \(Adult, 6% \)Reproductive: Dysmenorrhea \(Adult, 3% \), Erectile dysfunction \(Adult, 8% \)Other: Fatigue \(Adult, 10%; pediatric, 8% \)SeriousCardiovascular: Increased diastolic arterial pressure \(Adult, 4.8% to 12.6%; pediatric, 9.3% to 21.5% \), Increased systolic arterial pressure \(Adult, 4.2% to 12.4%; pediatric, 4.9% to 12.5% \), Myocardial infarction, Sudden cardiac death, Tachycardia \(Adult, 1.5%; pediatric, 0.3% \)Hepatic: Injury of liver \(Severe\), Liver failureNeurologic: Cerebrovascular accidentPsychiatric: Aggressive behavior, Hostile behavior, Mania, Psychotic disorder, Suicidal thoughts \(Pediatric, 0.4% \)Reproductive: Priapism |
| 禁忌 | Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma, current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure \(eg, 15 to 20 mm Hg\) or heart rate \(eg, 20 beats per minute\) |
| 藥物保存方式 | 25℃ |
| 用法用量 | 6 years or older, up to 70 kg: Acute treatment: Initial, approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily, as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; MAX 1.4 mg/kg daily or 100 mg/day, whichever is less 6 years or older, greater than 70 kg: Acute treatment: Initial, 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; MAX 100 mg daily |
| 肝功能異常 | 需 調 整 劑 量  \[仿單\]中度的肝功能不全病患\(Child-Pugh Class B\)，起始及目標劑量應為一般劑量的 50％。 患有嚴重肝功能不全\(Child-Pugh Class C\)的病患，起始及目標劑量應為一般劑量的 25％。 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | \[仿單\] 在懷孕兔子的器官形成期間，餵食劑量最高至 100 mg/ kg/ day 的Atomoxetine。在三篇研究中的一篇，觀察到活胎數減少，早期再吸收增加。不正常頸動脈起源及缺少鎖骨下動脈的發生率稍微增加。這些結果發現於會引起輕微母體毒性的劑量。 這些結果的無作用劑量（no-effect dose）為 30 mg/ kg/ day。以mg/ m2計，100 mg/ kg 的劑量約為最高人體劑量的 23 倍，兔子血中的 Atomoxetine濃度（AUC）估計為接受最高人體劑量的人體內的 3.3 倍（快速代謝者）或 0.4 倍（緩慢代謝者）。 從交配前 2 週（母鼠）或 10 週（公鼠），到器官形成及哺乳期為止，在老鼠飲食中加入不超過大約 50 mg/ kg/ day 的 atomoxetine（以 mg/ m2計算，約為最高人體劑量的 6 倍）。 在二篇研究的其中一篇，發現小鼠體重及存活數減少。在 25 mg/ kg（非 13 mg/ kg），也發現到小鼠的存活減少的現象。 一篇從交配前 2 週（母鼠）或10 週（公鼠），到器官形成期為止，在老鼠飲食中加入 Atomoxetine 的研究中，40mg/ kg/ day（以 mg/ m2計，約為最高人體劑量的 5 倍），發現到胎鼠體重減少（僅母鼠）及椎骨弓（vertebral arch）不完全成骨的發生率增加的現象，此現象並沒有在 20 mg/ kg/ day 劑量組中發現。 在器官形成期間，以 150 mg/ kg/ day 的劑量（以 mg/ m2計，約為最高人體劑量的17 倍）餵食懷孕母鼠，胎兒並未出現任何的副作用。 目前尚無關於懷孕婦女之充分及完整的對照性研究。 懷孕期間不可服用 Atomoxetine，除非效益超過胎兒可能產生的風險性。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。 |
| 注射劑給藥建議途徑 | AC, PC, PO, WM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 不應打開藥物膠囊須整顆服用:20200706查詢Strattera水劑仿單,上載"Atomoxetine具有眼部刺激性,若接觸眼睛需以大量清水沖洗並就醫.手或身體可能接觸到Atomoxetine的部位皆須盡快清洗." |

## Strattera 10mg

| 藥物代碼 | OSTR1 |
| :--- | :--- |
| 適應症 | Treatment of attention-deficit/hyperactivity disorder \(ADHD\). |
| 副作用 | Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence.Endocrine metabolic: Weight loss \(pediatrics, 7.1% to 29.1% \)Gastrointestinal: Abdominal pain \(adults, 7%; pediatrics, 17% to 18% \), Constipation \(adults, 9%; pediatric, 1% to 2%\), Decrease in appetite \(adult, 11%; pediatrics, 16% ,\), Nausea \(adults, 21%; pediatrics, 7% to 13% \), Vomiting \(adults, 3%; pediatrics, 11%\), Xerostomia \(adults, 21% \)Neurologic: Headache \(pediatrics, 19% \), Insomnia \(adults, 16%; pediatrics, at least 2%; \), Somnolence \(adult, 4%; pediatrics, 11% \)Renal: Delay when starting to pass urine \(adults, 5.6% \), Urinary retention \(adults, 1.7% \)Reproductive: Dysmenorrhea \(adults, 6% \), Erectile dysfunction \(adults, 9% \)Other: Menopausal flushing \(adults, 8% \) |
| 禁忌 | with a MAOI or within 2 weeks after discontinuing a MAOI, narrow-Angle Glaucoma. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult, adolescent & children &lt;70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg, whichever is less. &gt;70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg. |
| 肝功能異常 | 需 調 整 劑 量  中度肝功能不全患者 \(Child-Pugh B\): Initial and target doses should be reduced to 50% of the normal dose 重度肝功能不全患者 \(Child-Pugh C\): Initial and target doses should be reduced to 25% of the normal dose |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Strattera 25mg

| 藥物代碼 | OSTR2 |
| :--- | :--- |
| 適應症 | Treatment of attention-deficit/hyperactivity disorder \(ADHD\). |
| 副作用 | Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence.Endocrine metabolic: Weight loss \(pediatrics, 7.1% to 29.1% \)Gastrointestinal: Abdominal pain \(adults, 7%; pediatrics, 17% to 18% \), Constipation \(adults, 9%; pediatric, 1% to 2%\), Decrease in appetite \(adult, 11%; pediatrics, 16% ,\), Nausea \(adults, 21%; pediatrics, 7% to 13% \), Vomiting \(adults, 3%; pediatrics, 11%\), Xerostomia \(adults, 21% \)Neurologic: Headache \(pediatrics, 19% \), Insomnia \(adults, 16%; pediatrics, at least 2%; \), Somnolence \(adult, 4%; pediatrics, 11% \)Renal: Delay when starting to pass urine \(adults, 5.6% \), Urinary retention \(adults, 1.7% \)Reproductive: Dysmenorrhea \(adults, 6% \), Erectile dysfunction \(adults, 9% \)Other: Menopausal flushing \(adults, 8% \) |
| 禁忌 | with a MAOI or within 2 weeks after discontinuing a MAOI, narrow-Angle Glaucoma. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult, adolescent & children &lt;70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg, whichever is less. &gt;70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg. |
| 肝功能異常 | 需 調 整 劑 量  中度肝功能不全患者 \(Child-Pugh B\): Initial and target doses should be reduced to 50% of the normal dose 重度肝功能不全患者 \(Child-Pugh C\): Initial and target doses should be reduced to 25% of the normal dose |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## STRATTERA 40MG

| 藥物代碼 | OSTR4 |
| :--- | :--- |
| 適應症 | Treatment of attention-deficit/hyperactivity disorder \(ADHD\). |
| 副作用 | Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence.Endocrine metabolic: Weight loss \(pediatrics, 7.1% to 29.1% \)Gastrointestinal: Abdominal pain \(adults, 7%; pediatrics, 17% to 18% \), Constipation \(adults, 9%; pediatric, 1% to 2%\), Decrease in appetite \(adult, 11%; pediatrics, 16% ,\), Nausea \(adults, 21%; pediatrics, 7% to 13% \), Vomiting \(adults, 3%; pediatrics, 11%\), Xerostomia \(adults, 21% \)Neurologic: Headache \(pediatrics, 19% \), Insomnia \(adults, 16%; pediatrics, at least 2%; \), Somnolence \(adult, 4%; pediatrics, 11% \)Renal: Delay when starting to pass urine \(adults, 5.6% \), Urinary retention \(adults, 1.7% \)Reproductive: Dysmenorrhea \(adults, 6% \), Erectile dysfunction \(adults, 9% \)Other: Menopausal flushing \(adults, 8% \) |
| 禁忌 | with a MAOI or within 2 weeks after discontinuing a MAOI, narrow-Angle Glaucoma. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult, adolescent & children &lt;70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg, whichever is less. &gt;70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg. |
| 肝功能異常 | 需 調 整 劑 量  中度肝功能不全患者 \(Child-Pugh B\): Initial and target doses should be reduced to 50% of the normal dose 重度肝功能不全患者 \(Child-Pugh C\): Initial and target doses should be reduced to 25% of the normal dose |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

